

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Alipza 4mg film-coated tablets.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains pitavastatin calcium equivalent to 4mg pitavastatin.

Excipient(s) include 252.34mg Lactose monohydrate.

For a full list of excipients see Section 6.1.

3 PHARMACEUTICAL FORM

Film-coated tablet.

Round white film-coated tablets embossed 'KC' on one face and '4' on the reverse.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Alipza is indicated for the reduction of elevated total cholesterol (TC) and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures is inadequate.

4.2 Posology and method of administration

For oral use only and should be swallowed whole. Alipza can be taken at any time of the day with or without food. It is desirable that the patient takes the tablet at the same time each day. Statin therapy is generally more effective in the evening due to the circadian rhythm of lipid metabolism. Patients should be on a cholesterol lowering diet before treatment. It is important that patients continue dietary control during treatment.

Adults:	The usual starting dose is 1mg once daily. Adjustment of dose should be made at intervals of 4 weeks or more. Doses should be individualized according to LDL-C Levels, the goal of therapy and patient response. Most Patients will require a 2mg dose (see Section 5.1). The Maximum daily dose is 4mg.
---------	---

Elderly:	No dosage adjustment is required (see Sections 5.1 and 5.2).
----------	--

Paediatric use:	Pitavastatin should not be used in children aged below 18 years because safety and efficacy has not been established. No data are currently available.
-----------------	--

Patients with impaired renal function:	No dosage adjustment is required in mild renal impairment but pitavastatin should be used with caution. Data with 4mg dose are limited in all
--	---

grades of impaired renal function. Therefore 4mg dose should ONLY be used with close monitoring after graded dose titration. In those with severe renal impairment 4mg dose is not recommended (see Sections 4.4 and 5.2).

Patients with mild to moderate impaired hepatic function:

The 4mg dose is not recommended in patients with mild to moderate impaired hepatic function. A maximum daily dose of 2mg may be given with close monitoring (see Sections 4.4 and 5.2).

4.3 Contraindications

Alipza is contraindicated:

- in patients with known hypersensitivity to pitavastatin or to any of the excipients or other statins
- in patients with severe hepatic impairment, active liver disease or unexplained persistent elevations in serum transaminases (exceeding 3 times the upper limit of normal [ULN])
- in patients with myopathy
- in patients receiving concomitant ciclosporin
- during pregnancy, while breast feeding and in women of child bearing potential not taking appropriate contraceptive precautions

4.4 Special warnings and precautions for use

Muscle Effects

In common with other HMG-CoA reductase inhibitors (statins), there is the potential for myalgia, myopathy and, rarely, rhabdomyolysis to develop. Patients should be asked to report any muscle symptoms. Creatine kinase (CK) levels should be measured in any patient reporting muscle pain, muscle tenderness or weakness especially if accompanied by malaise or fever.

Creatine kinase should not be measured following strenuous exercise or in the presence of any other plausible cause of CK increase which may confound interpretation of the result. When elevated CK concentrations ($>5\times$ ULN) are noted, a confirmatory test should be performed within 5 to 7 days.

Before Treatment

In common with other statins, Alipza should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. A creatinine kinase level should be measured, to establish a reference baseline, in the following situations:

- renal impairment,
- hypothyroidism,
- personal or family history of hereditary muscular disorders,
- previous history of muscular toxicity with a fibrate or another statin,
- history of liver disease or alcohol abuse,
- elderly patients (over 70 years) with other predisposing risk factors for rhabdomyolysis,

In such situations, clinical monitoring is recommended and the risk of treatment should be considered in relation to the possible benefit. Treatment with Alipza should not be started if CK values are $>5\times$ ULN.

During Treatment

Patients must be encouraged to report muscle pain, weakness or cramps immediately. Creatine kinase levels should be measured and treatment stopped if CK levels are elevated ($>5\times$ ULN). Stopping treatment should be considered if muscular symptoms are severe even if CK levels are $\leq 5\times$ ULN. If symptoms resolve and CK levels return to normal, then re-introduction of Alipza may be considered at a dose of 1mg and with close monitoring.

Liver Effects

In common with other statins, Alipza should be used with caution in patients with a history of liver disease or who regularly consume excessive quantities of alcohol. Liver function tests should be performed prior to initiating treatment with Alipza and then periodically during treatment. Alipza treatment should be discontinued in patients who have a persistent increase in serum transaminases (ALT and AST) exceeding 3x ULN.

Renal Effects

Alipza should be used with caution in patients with moderate or severe renal impairment. Dose increments should be instituted only with close monitoring. In those with severe renal impairment, 4mg dose is not recommended (see Section 4.2).

Diabetes Mellitus

Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk of hyperglycaemia (fasting glucose 5.6 to 6.9 mmol/L, BMI > 30 kg/m², raised triglycerides, hypertension), should be monitored both clinically and biochemically according to national guidelines.

Interstitial Lung Disease

Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see Section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.

Other effects

A temporary suspension of Alipza is recommended for the duration of treatment with erythromycin, other macrolide antibiotics or fusidic acid (see Section 4.5). Alipza should be used with caution in patients taking drugs known to cause myopathy (e.g. fibrates or niacin see Section 4.5).

The tablets contain lactose. Patients with the rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Pitavastatin is actively transported into human hepatocytes by multiple hepatic transporters (including organic anion transporting polypeptide, OATP), which may be involved in some of the following interactions.

Ciclosporin: Co-administration of a single dose of ciclosporin with Alipza at steady state resulted in a 4.6-fold increase in pitavastatin AUC. The effect of steady state ciclosporin on steady state Alipza is not known. Alipza is contraindicated in patients being treated with ciclosporin (see section 4.3).

Erythromycin: Co-administration with Alipza resulted in a 2.8-fold increase in pitavastatin AUC. A temporary suspension of Alipza is recommended for the duration of treatment with erythromycin or other macrolide antibiotics.

Gemfibrozil and other fibrates: The use of fibrates alone is occasionally associated with myopathy. Co-administration of fibrates with statins has been associated with increased myopathy and rhabdomyolysis. Alipza should be administered with caution when used concomitantly with fibrates (see Section 4.4). In Pharmacokinetic studies co-administration of Alipza with Gemfibrozil resulted in a 1.4-fold increase in pitavastatin AUC with Fenofibrate AUC increased 1.2-fold.

Niacin: Interaction studies with Alipza and niacin have not been conducted. The use of niacin alone has been associated with myopathy and rhabdomyolysis when used as a monotherapy.

Thus Alipza should be administered with caution when used concomitantly with niacin.

Fusidic acid: There have been reports of severe muscle problems such as rhabdomyolysis attributed to interactions

between fusidic acid and statins. A temporary suspension of Alipza is recommended for the duration of treatment with fusidic acid (see section 4.4).

Rifampicin: Co-administration with Alipza at the same time resulted in a 1.3-fold increase in pitavastatin AUC due to reduced hepatic uptake

Protease inhibitors: Co-administration with Alipza at the same time may result in minor changes in pitavastatin AUC.

Ezetimibe and its glucuronide metabolite inhibit the absorption of dietary and biliary cholesterol. Co-administration of Alipza had no effect on plasma ezetimibe or the glucuronide metabolite concentrations and ezetimibe had no impact on pitavastatin plasma concentrations.

Inhibitors of CYP3A4: Interaction studies with itraconazole and grapefruit juice, known inhibitors of CYP3A4, had no clinically significant effect on the plasma concentrations of pitavastatin.

Digoxin, a known P-gp substrate, did not interact with Alipza. During co-administration there was no significant change in either pitavastatin or digoxin concentrations.

Warfarin: The steady-state pharmacokinetics and pharmacodynamics (INR and PT) of warfarin in healthy volunteers was unaffected by the co-administration of Alipza 4mg daily. However, as for other statins, patients receiving warfarin should have their prothrombin time or INR monitored when Alipza is added to their therapy.

4.6 Fertility, pregnancy and lactation

Pregnancy

Alipza is contraindicated during pregnancy (see Section 4.3). Women of childbearing potential must take appropriate contraceptive precautions during treatment with Alipza. Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the fetus, the potential risk for inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies show evidence of reproductive toxicity, but no teratogenic potential (see Section 5.3). If the patient is planning to become pregnant, treatment should be stopped at least one month prior to conception. If a patient becomes pregnant during use of Alipza, treatment must be discontinued immediately.

Lactation

Alipza is contraindicated during lactation (see Section 4.3). Pitavastatin is excreted in rat milk. It is not known whether it is excreted in human milk.

4.7 Effects on ability to drive and use machines

There is no pattern of adverse events that suggests that patients taking Alipza will have any impairment of ability to drive and use hazardous machinery, but it should be taken into account that there have been reports of dizziness and somnolence during treatment with Alipza.

4.8 Undesirable effects

Summary of the safety profile

In controlled clinical trials, at the recommended doses, less than 4% of Alipza treated patients were withdrawn due to adverse events. The most commonly reported pitavastatin related adverse reaction in controlled clinical trials was myalgia.

Summary of adverse reactions

Adverse reactions and frequencies observed in worldwide controlled clinical trials and extension studies, at the recommended doses, are listed below by system organ class. Frequencies are defined as: very common ($\geq 1/10$), common ($\geq 1/100$, to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) very rare ($< 1/10,000$) and

not known.

Blood and the lymphatic system disorders

Uncommon: Anaemia

Metabolism and nutrition disorders

Uncommon: Anorexia

Psychiatric disorders

Uncommon: Insomnia

Nervous system disorders

Common: Headache

Uncommon: Dizziness, Dysgeusia, Somnolence

Eye disorders

Rare: Visual acuity reduced

Ear and labyrinth disorders

Uncommon: Tinnitus

Gastrointestinal disorders

Common: Constipation, Diarrhoea, Dyspepsia, Nausea

Uncommon: Abdominal Pain, Dry Mouth, Vomiting

Rare: Glossodynia, pancreatitis acute

Hepato-biliary disorders

Uncommon: Transaminases (aspartate aminotransferase, alanine aminotransferase) increased

Rare: Jaundice cholestatic

Skin and subcutaneous tissue disorders

Uncommon: Pruritus, Rash

Rare: Urticaria, Erythema

Musculoskeletal, connective tissue and bone disorders

Common: Myalgia, Arthralgia

Uncommon: Muscle spasms

Renal and urinary disorders

Uncommon: Pollakiuria

General disorders and administration site conditions

Uncommon: Asthenia, Malaise, Fatigue, Peripheral Oedema

Elevated blood creatinine kinase of >3 times the upper limit of normal (ULN) occurred in 49 out of 2800 (1.8%) patients receiving Alipza in the controlled clinical trials. Levels of ≥ 10 times ULN with concurrent muscle symptoms were rare and only observed in one patient out of 2406 treated with 4mg Alipza (0.04%) in the clinical trial programme.

Post Marketing Experience

A two year prospective post-marketing surveillance study was conducted in nearly 20,000 patients in Japan. The overwhelming majority of the 20,000 patients in the study were treated with 1mg or 2mg pitavastatin and not 4mg. 10.4% of patients reported adverse events for which a causal relationship to pitavastatin could not be ruled out and 7.4% of patients withdrew from therapy due to adverse events. The myalgia rate was 1.08%. The majority of adverse events were mild. Adverse event rates were higher over 2 years in patients with a history of drug allergy (20.4%), or hepatic or renal disease (13.5%).

Adverse reactions and frequencies observed in the prospective post-marketing surveillance study but not in worldwide controlled clinical trials, at the recommended doses are listed below.

Hepato-biliary disorders

Rare: Hepatic function abnormal, Liver disorder

Musculoskeletal, connective tissue disorders

Rare: Myopathy, Rhabdomyolysis

In the post-marketing surveillance study there were two reports of rhabdomyolysis requiring hospitalisation (0.01% of patients).

In addition there are unsolicited post-marketing reports of skeletal muscle effects including myalgia and myopathy in Alipza treated patients at all recommended doses. Reports of rhabdomyolysis, with and without acute renal failure, including fatal rhabdomyolysis have also been received. Unsolicited reports of the following events have also been received (the frequency is based on that observed in post-marketing studies):

Nervous system disorders

Uncommon: Hypoaesthesia

Gastrointestinal disorders

Rare: Abdominal discomfort

Statin class effects

The following adverse events have been reported with some statins:

- Sleep disturbances, including nightmares
- Memory loss
- Sexual dysfunction
- Depression
- Exceptional cases of interstitial lung disease, especially with long term therapy (see Section 4.4)
- Diabetes Mellitus: Frequency will depend on the presence or absence of risk factors (fasting blood glucose ≥ 5.6 mmol/L, BMI >30 kg/m², raised triglycerides, history of hypertension)

4.9 Overdose

There is no specific treatment in the event of overdose. The patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: HMG-CoA reductase inhibitors

ATC Code: C10A A08

Mechanism of Action

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver. As a result the expression of LDL receptors in the liver is increased, promoting the uptake of circulating LDL from the blood, decreasing total cholesterol (TC) and LDL-cholesterol (LDL-C) concentrations in the blood. Its sustained inhibition of hepatic cholesterol synthesis reduces VLDL secretion into the blood, reducing plasma triglyceride (TG) levels.

Pharmacodynamic Effects

Alipza reduces elevated LDL-C, total cholesterol and triglycerides and increases HDL-cholesterol (HDL-C).

It reduces Apo-B, and produces variable increases in Apo-A1 (see Table 1). It also reduces non-HDL-C and elevated TC/HDL-C, and Apo-B/Apo-A1 ratios.

**Table 1: Dose response in patients with primary hypercholesterolaemia
(Adjusted mean percent change from baseline over 12 weeks)**

Dose	N	LDL-C	TC*	HDL-C	TG	Apo-B	Apo-A1
Placebo	51	-4.0	-1.3	2.5	-2.1	0.3	3.2
1mg	52	-33.3	-22.8	9.4	-14.8	-24.1	8.5
2mg	49	-38.2	-26.1	9.0	-17.4	-30.4	5.6
4mg	50	-46.5	-32.5	8.3	-21.2	-36.1	4.7

*unadjusted

Clinical efficacy

In controlled clinical studies which enrolled a total of 1687 patients with primary hypercholesterolaemia and mixed dyslipidaemia, including 1239 patients treated at the therapeutic doses (mean baseline LDL-C about 4.8 mmol/L), Alipza consistently reduced LDL-C, TC, non-HDL-C, TG and Apo-B concentrations and elevated HDL-C and Apo-A1 concentrations. TC/HDL-C and Apo-B/Apo-A1 ratios were reduced. LDL-C was reduced by 38 to 39% with Alipza 2mg and 44 to 45% with Alipza 4mg. The majority of patients taking 2mg achieved the European Atherosclerosis Society (EAS) treatment target for LDL-C (<3 mmol/L).

In a controlled clinical trial in 942 patients aged ≥65 years (434 treated with Alipza 1mg, 2mg or 4mg) with primary hypercholesterolaemia and mixed dyslipidaemia (mean baseline LDL-C about 4.2 mmol/L), LDL-C values were reduced by 31%, 39.0% and 44.3%, respectively, and about 90% of patients reached the EAS treatment target. More than 80% of the patients were taking concomitant medications, but the incidence of adverse events was similar in all treatment groups and fewer than 5% of patients withdrew from the study due to adverse events. Safety and efficacy findings were similar in patients in the different age subgroups (65-69, 70-74, and ≥75 years).

In controlled clinical trials which enrolled a total of 761 patients (507 treated with Alipza 4mg) who had primary hypercholesterolaemia or mixed dyslipidaemia, with 2 or more cardiovascular risk factors (mean baseline LDL-C about 4.1 mmol/L), or mixed dyslipidaemia with type 2 diabetes (mean baseline LDL-C about 3.6 mmol/L), approximately 80% achieved the relevant EAS target (either 3 or 2.5 mmol/L, depending on risk). LDL-C was reduced by 44% and 41%, respectively, in the patient groups.

In long term studies of up to 60 weeks duration in primary hypercholesterolaemia and mixed dyslipidaemia, EAS target attainment has been maintained by persistent and stable reductions of LDL-C, and HDL-C concentrations have continued to increase. In a study in 1346 patients who had completed 12 weeks of statin therapy (LDL-C reduction 42.3%, EAS target attainment 69%, HDL-C elevation 5.6%), values after a further 52 weeks of treatment with pitavastatin 4mg were LDL-C reduction 42.9%, EAS target attainment 74%, HDL-C elevation 14.3%.

A beneficial effect of pitavastatin on cardiovascular morbidity and mortality has not been demonstrated as no outcome studies were included in the clinical programme.

5.2 Pharmacokinetic properties

Absorption: Pitavastatin is rapidly absorbed from the upper gastrointestinal tract and peak plasma concentrations are achieved within one hour after oral administration. Absorption is not affected by food. Unchanged drug undergoes enterohepatic circulation and is well absorbed from the jejunum and ileum. The absolute bioavailability of pitavastatin is 51%.

Distribution: Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 133 L. Pitavastatin is actively transported into

hepatocytes, the site of action and metabolism, by multiple hepatic transporters including OATP1B1 and OATP1B3. Plasma AUC is variable with an approximately 4-fold range between the highest and lowest values. Studies with SLCO1B1 (the gene which encodes OATP1B1) suggests that polymorphism of this gene could account for much of the variability in AUC. Pitavastatin is not a substrate for p-glycoprotein.

Metabolism: Unchanged pitavastatin is the predominant drug moiety in plasma. The principal metabolite is the inactive lactone which is formed via an ester-type pitavastatin glucuronide conjugate by UDP glucuronosyltransferase (UGT1A3 and 2B7). In vitro studies, using 13 human cytochrome P450 (CYP) isoforms, indicate that the metabolism of pitavastatin by CYP is minimal; CYP2C9 (and to a lesser extent CYP2C8) is responsible for the metabolism of pitavastatin to minor metabolites.

Excretion: Unchanged pitavastatin is rapidly cleared from the liver in the bile, but undergoes enterohepatic recirculation, contributing to its duration of action. Less than 5% of pitavastatin is excreted in the urine. The plasma elimination half-life ranges from 5.7 hours (single dose) to 8.9 hours (steady state) and the apparent geometric mean oral clearance is 43.4 L/h after single dose.

Effect of food: The maximum plasma concentration of pitavastatin was reduced by 43% when it was taken with a high-fat meal, but AUC was unchanged.

Special populations

Elderly: In a pharmacokinetic study which compared healthy young and elderly (≥ 65 years) volunteers, pitavastatin AUC was 1.3-fold higher in elderly subjects. This has no effect on the safety or efficacy of Alipza in elderly patients in clinical trials.

Gender: In a pharmacokinetic study which compared healthy male and female volunteers, pitavastatin AUC was increased 1.6-fold in women. This has no effect on the safety or efficacy of Alipza in women in clinical trials.

Race: There was no difference in the pharmacokinetic profile of pitavastatin between Japanese and Caucasian healthy volunteers when age and body weight was taken into account.

Paediatric: Pharmacokinetic data in the paediatric population are not available.

Renal insufficiency: For patients with moderate renal disease and those on haemodialysis increases in AUC values were 1.8-fold and 1.7-fold respectively (see Section 4.2).

Hepatic insufficiency: For patients with mild (Child-Pugh A) hepatic impairment AUC was 1.6 times that in healthy subjects, while for patients with moderate (Child-Pugh B) hepatic impairment AUC was 3.9-fold higher. Dose restrictions are recommended in patients with mild and moderate hepatic impairment (see Section 4.2). Alipza is contraindicated in patients with severe hepatic impairment.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on results from conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Indications of renal toxicity were seen in monkeys at exposures greater than those reached in adult humans administered the maximum daily dose of 4mg and urinary excretion plays a far greater role in the monkey than in other animal species. In vitro studies with liver microsomes indicate that a monkey-specific metabolite may be implicated. The renal effects observed in monkeys are unlikely to have clinical relevance for humans, however the potential for renal adverse reactions cannot be completely excluded.

Pitavastatin had no effect on fertility or reproductive performance and there was no evidence of teratogenic potential. However, maternal toxicity was observed at high doses.

A study in rats indicated maternal mortality at or near term accompanied by fetal and neonatal deaths at doses of 1 mg/kg/day (approximately 4 fold greater than the highest dose in humans on an AUC basis). No studies have been conducted in juvenile animals.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core

Lactose monohydrate
Low substituted hydroxypropylcellulose
Hypromellose (E464)
Magnesium Aluminometasilicate
Magnesium stearate

Film coating

Hypromellose (E464)
Titanium dioxide (E171)
Triethyl citrate (E1505)
Colloidal anhydrous silica

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

4 years.

6.4 Special precautions for storage

Do not store above 25°C.

To protect from light keep blister in the outer carton.

6.5 Nature and contents of container

White PVdC coated PVC/AL blisters in cartons of 7, 28 or 30 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

To protect the environment, do not dispose of via waste water or household waste.

7 MARKETING AUTHORISATION HOLDER

Kowa Pharmaceutical Europe Co. Ltd.,
Winnersh Triangle, Wokingham RG41 5RB, UK.

8 MARKETING AUTHORISATION NUMBER

PA 1532/2/2

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 5th November 2010

10 DATE OF REVISION OF THE TEXT

October 2012